$5145 | Single User
$7725 | Global License

Market Access Impact (EU5)
[Myeloma]
[Report Updated: 01-09-2017]

Published by FirstWord Pharma: 01 Sep 2017 | 150157 | In Stock
Related Topics: Multiple Myeloma , Myeloma , Novartis

Introduction



Find out why doctors can’t prescribe your brand, and what you can do about it

Market barriers only affect 19% of multiple myeloma prescriptions in the EU5 countries, and the split between brands that gain and lose market share because of them is pretty even. But a willingness to prescribe certain brands, and high levels of awareness, could be the light at the end of the tunnel for companies promoting multiple myeloma treatments in the EU5 markets.

Find out how doctors see your brand, and whether market barriers are dragging your market share down, in Market Access Impact: Multiple Myeloma (EU5).

Based on a survey of 150 medical oncologists and haematologists, the report covers 7 major therapies from Janssen Biotech, Genmab, Novartis, Amgen, Takeda and Celgene. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Not your market? Click here to see the US Edition.

Request sample pages



Top Takeaways

No clear winners or losers. Of the 7 brands included in the survey, 4 gain market share and 3 lose market share. Where does your brand come in the pecking order?

No one barrier is to blame. Most of the 7 barriers covered in the report affect the same amount of prescriptions.

Barrier impact is small. Over 45-65% of surveyed doctors experience only one barrier with any given brand, but for some brands that climbs to 3 barriers.

Cost isn’t the biggest barrier. While treatment costs do have an impact on prescribing patterns, two other barriers have more of an impact; find out what they are.

Understanding the fine margins could be the difference. The overall barrier impact in EU5 markets is smaller compared to the US, but knowing what commercial levers to pull could make all the difference.

Insight into 7 Major Multiple Myeloma Treatments

Darzalex (daratumumab; Janssen Cilag/Genmab)

Farydak (panobinostat; Novartis)

Kyprolis (carfilzomib; Amgen)

Imnovid (pomalidomide; Celgene)

Revlimid (lenalidomide; Celgene)

Thalidomide (thalidomide; Celgene)

Velcade (bortezomib; Takeda)

Exploring Market Access Barriers

Market Access Impact: Multiple Myeloma (EU5) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?

How many prescriptions do barriers affect?

Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?

Why don’t doctors prescribe your brand? What do they prescribe instead?

Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

Market Access Impact: Multiple Myeloma (EU5) explores key issues affecting drug manufacturers. You’ll learn:

All respondents:

Have been practicing for 2+ years

Prescribed at least one of the listed products

Seen at least 5 patients with NSCLC in total in the last month

We conducted the survey between September 1-12, 2017

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents
for Market Access Impact (EU5) [Myeloma] [Report Updated: 01-09-2017]

  • 1.What are market barriers?

    2.About this report

    3.About the survey

    4.Brands included in the survey

    5.Executive summary

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

150157 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Market Access Excellence for Emerging Markets
IntroductionWhat knowledge, strategies, and resources do you need right now to maximise your company...
01 May 2015 by FirstWord Pharma USD $2,195 More Info
Expanded Access Programs: Opportunities and Challenges for Pharma
IntroductionExpanded access programmes make available investigational drugs to chronically sick or d...
20 Apr 2015 by FirstWord Pharma USD $595 More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
Market Access Team Management: driving exceptional performance
IntroductionThe demands on market access teams are growing rapidly as the specific needs of key stak...
12 Aug 2014 by FirstWord Pharma USD $695 More Info
Oncology Market Access Europe – Payer and Industry Perspectives
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
03 Jul 2014 by FirstWord Pharma USD $995 More Info
Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
28 Apr 2014 by FirstWord Pharma USD $695 More Info
The Reality of Market Access in Europe: the role of Health Technology Assessment
IntroductionFaced with slipping or negligible GDP growth and an economic crisis, Eurozone countries ...
10 Mar 2014 by FirstWord Pharma USD $695 More Info
Market Access for Orphan Drugs: assessing the global landscape
IntroductionTheir development costs can be high and the market is relative small, yet orphan drugs r...
01 Dec 2013 by FirstWord Pharma USD $695 More Info
Market Access in the EU5 – a comparative overview
IntroductionThe sustained and challenging economic environment in the EU has impacted – and is impac...
01 Aug 2013 by FirstWord Pharma USD $395 More Info
Market Access: Communicating Value Stories to Payers
IntroductionThroughout the EU, reimbursement decisions are increasingly decentralised, making the pr...
01 Apr 2012 by FirstWord Pharma USD $695 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Market Access Impact (EU5) [Myeloma] [Report Updated: 01-09-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...